Cadila Unveils Vasograin Plus for Fast, Dual-Action Migraine Relief

In a major leap forward for migraine treatment, Cadila Pharmaceuticals has launched Vasograin Plus, a powerful dual-action therapy for the acute treatment of migraine, with or without aura, in adults and adolescents.

This cutting-edge formulation brings hope to millions who struggle with debilitating migraine episodes and are in need of faster, longer-lasting relief.

Vasograin Plus is a fixed-dose combination that blends a selective serotonin receptor agonist and a non-steroidal anti-inflammatory drug (NSAID), delivering a synergistic effect against the neurological and inflammatory roots of migraine.

Also Read: Anti-Infectives: How New Research is Shaping Infection Control

By targeting both pain signaling and inflammation, it helps to constrict cranial blood vessels, reduce trigeminal nerve sensitivity, and significantly lower the chances of migraine recurrence.

Dr. Rajiv I. Modi, Chairman & Managing Director of Cadila Pharmaceuticals, emphasized the company’s mission, saying, “At Cadila Pharmaceuticals, we believe healthcare should not just treat, but empower. Vasograin Plus is the result of rigorous science, patient needs, and our unwavering focus on innovation.”

What sets Vasograin Plus apart in the migraine treatment landscape is its rapid onset of action, extended relief duration, and improved patient compliance, all delivered in a single, convenient tablet. For those managing episodic or chronic migraines, this innovation offers greater control and reduced dependency on multiple medications.

With Vasograin Plus, Cadila Pharmaceuticals reinforces its commitment to driving accessible, research-driven therapies that transform the lives of people living with migraine.